This vaccine formulation, termed as Nano-liposomal Immunogenic Fused PCSK9-Tetanus with alum vaccine adjuvant (L-IFPTA+) was tested in mice with dyslipidaemia, where it inhibits the interaction between PCSK9 and LDLR and reduces the progression of atherosclerosis with long term immunity effects and efficacy [158]. This evidence concerns the gene LDLR and atherosclerosis.